Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy

NCT02940639 · clinicaltrials.gov ↗
COMPLETED
Status
499
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

Bristol-Myers Squibb